Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 28, 2023Reports of Practical Oncology & RadiotherapyOpen Access

Angiotensin-converting enzyme inhibitors for ovarian cancer? — a new adjuvant option or a silent trap

View Full Paper
Ask AI
Bookmark
Share

Key result

Available data warrant further research into repositioning angiotensin-converting enzyme inhibitors as chemosensitizers for ovarian cancer, provided potential genotoxic contaminants are investigated.

Why the study?

Approved treatments for ovarian cancer have reached their limit of efficiency, motivating the evaluation of drug repurposing strategies such as ACE-Is to overcome chemoresistance.

Design

Literature review, TCGA database analysis, and in silico structure-activity relationship evaluation

Authors

KRKatarzyna RegulskaGreater Poland Cancer CenterMMMarcin MichalakGreater Poland Cancer CenterTKTomasz KolendaGreater Poland Cancer Center

Discussion

Loading...

Member takes

Overview

ACE-Is should not yet change practice in ovarian cancer; leaves open hypothesis of chemosensitization pending prospective trials and genotoxicity assessment.

Structured PICO

P
Population
A review of preclinical, clinical, and in silico data evaluating the potential of angiotensin-converting enzyme inhibitors as adjuvant therapy for ovarian cancer.
I
Intervention
Angiotensin-converting enzyme inhibitors (ACE-Is) as adjuvant therapy or chemosensitizers
O
Outcome
Cytotoxicity against ovarian cancer cells, patient survival, and cancer incidence

Available data warrant further research into repositioning ACE-Is as chemosensitizers for ovarian cancer, provided potential genotoxic contaminants are investigated.

Limitations

  • Lack of dedicated confirmatory clinical studies for ACE-Is specifically in ovarian cancer.
  • Conflicting results regarding the prophylactic application of ACE-Is in gynecologic malignancies.
  • Potential presence of mutagenic nitrosamine impurities in ACE-I formulations that require urgent safety verification.

Cite This Study

Regulska et al. (2023) conducted a review in Ovarian cancer. Angiotensin-converting enzyme inhibitors (ACE-Is) vs. Standard chemotherapy or antiangiogenic therapy alone was evaluated. Available data warrant further research into repositioning angiotensin-converting enzyme inhibitors as chemosensitizers for ovarian cancer, provided potential genotoxic contaminants are investigated.

synapsesocial.com/papers/6a74c78596d04a2f43f557efhttps://doi.org/10.5603/rpor.a2023.0059
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of ACE (Angiotensin-Converting Enzyme) Inhibitors and Risk of Lung Cancer2021 · 32 citations
  2. 2Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Cancer: A Population-Based Cohort Study Using a Common Data Model2022 · 14 citations
  3. 3Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials2022 · 28 citations
  4. 4Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer2022 · 31 citations
  5. 5Cancer incidence and mortality in Poland2019 · 38 citations